ATF6 Controls Endothelial Inflammation After Hepatectomy via TRIM10/NF-κB

Study Background and Research Question

Post-hepatectomy liver failure (PHLF) and small-for-size syndrome (SFSS) are severe complications following extensive liver resection, with morbidity and mortality rates reaching up to 40–60% in affected patients. A key pathological contributor is excessive, unresolved inflammation in liver sinusoidal endothelial cells (LSECs), which undermines liver regeneration and homeostasis. While clinical interventions such as portal vein embolization aim to mitigate these risks, the molecular mechanisms driving endothelial inflammation after extended hepatectomy remain incompletely understood. The unfolded protein response (UPR), a cellular adaptation to endoplasmic reticulum (ER) stress, has emerged as a potential regulator of endothelial and hepatic function in this setting. In particular, the role of activating transcription factor 6 (ATF6), one of the three canonical UPR branches, in modulating endothelial inflammation had not been fully elucidated prior to this study.

Key Innovation from the Reference Study

The reference study (Shi et al., 2025) establishes that ATF6 activation in LSECs is critical for suppressing inflammation after extended (80%) hepatectomy in mice and correlates with improved outcomes in human patients. The researchers identify a novel mechanistic axis: ATF6 negatively regulates tripartite motif–containing protein 10 (TRIM10), which in turn modulates the nuclear factor-κB (NF-κB) inflammatory pathway. This work provides direct evidence that ATF6 acts as a transcriptional repressor of TRIM10, leading to dampened NF-κB signaling and reduced endothelial inflammation. The study thereby bridges ER stress signaling and inflammatory control in the vascular endothelium during acute liver injury.

Methods and Experimental Design Insights

The authors combined clinical data and rigorous animal modeling. Human gene expression data were collected from patients undergoing marginal hepatectomy, while murine models underwent 80% hepatectomy to mimic extended surgical resection. To dissect molecular mechanisms in vitro, human umbilical vein endothelial cells (HUVECs) were treated with ER stress modulators, including tunicamycin (a well-characterized N-glycosylation inhibitor and endoplasmic reticulum stress inducer) and lipopolysaccharide (LPS) to induce inflammatory signaling. Both genetic (global and LSEC-specific knockout) and pharmacological (ATF6 antagonist Ceapin-A7, ATF6 agonist AA147) approaches were used to modulate ATF6 activity. Downstream effects on TRIM10 and NF-κB signaling were assessed using quantitative RT-PCR, western blotting, chromatin immunoprecipitation (ChIP), and functional assays for endothelial injury and inflammation.

Protocol Parameters

• Hepatectomy model: 80% resection in C57BL/6 mice to simulate extended hepatic injury.
• ER stress induction: Tunicamycin treatment in HUVECs (dose and timing not specified in abstract; see product information for typical concentrations and workflows).
• ATF6 modulation: Genetic knockout (global and LSEC-specific) and pharmacological inhibition (Ceapin-A7) or activation (AA147).
• Endothelial inflammation assay: LPS challenge in vitro to evaluate inflammatory mediator expression and cell injury.

Core Findings and Why They Matter

Key discoveries from the reference study include:

• ATF6 upregulation in LSECs: Both mouse and human LSECs showed marked ATF6 activation after major hepatectomy.
• ATF6 is protective: Mice with ATF6 deficiency (global knockout or LSEC-specific knockdown) failed to resolve inflammation, developed more severe liver injury, and had exacerbated endothelial dysfunction.
• TRIM10/NF-κB axis: ATF6 suppresses TRIM10 at the transcriptional level, thereby inhibiting downstream NF-κB activation and inflammatory gene expression (including IL-6 and TNF-α).
• Pharmacological validation: In endothelial cells, ATF6 inhibition (Ceapin-A7 or knockout) increased inflammation, whereas ATF6 activation (AA147) reduced inflammatory responses.
• Role of ER chaperones: ER stress markers, such as GRP78, were modulated in parallel with ATF6 activity, supporting the link between UPR signaling and vascular inflammation.

These findings clarify why some patients suffer uncontrolled inflammation and poor outcomes after liver surgery, revealing a critical molecular checkpoint that could be targeted therapeutically to improve postoperative recovery.

Comparison with Existing Internal Articles

Several recent reviews and workflow guides have highlighted tunicamycin as a benchmark protein N-glycosylation inhibitor and inflammation suppression tool in diverse models. For instance, the article "Tunicamycin: Optimizing ER Stress and Inflammation Assays" discusses best practices for leveraging tunicamycin to dissect ER stress and inflammation in RAW264.7 macrophages, emphasizing gene expression and reproducibility. The new evidence from Shi et al. extends these principles to liver endothelial cells and directly links ATF6-driven UPR modulation to suppression of the TRIM10/NF-κB axis. Similarly, "Tunicamycin: Strategic Mechanistic Insight for Advancing..." contextualizes tunicamycin’s impact on inflammation and stem cell mobilization via ER stress, echoing the mechanistic depth now demonstrated in hepatic endothelium. These resources together underscore the utility of tunicamycin in modeling ER stress–mediated inflammation, now validated at the level of vascular endothelium in the context of liver injury.

Limitations and Transferability

While the study offers robust mechanistic insight, several limitations should be considered. The in vivo findings are based primarily on murine models, and while human LSEC gene expression was assessed, the direct clinical translation warrants further investigation. Additionally, the dose, timing, and cell-type specificity of ER stress induction (e.g., with tunicamycin) may differ between experimental and therapeutic contexts. The observed regulatory relationship between ATF6, TRIM10, and NF-κB may also be modulated by additional cell-intrinsic or microenvironmental factors not fully explored in this study.

Research Support Resources

Researchers aiming to model ER stress–induced inflammation or to dissect the UPR’s role in endothelial function can employ tunicamycin as a reference N-glycosylation inhibitor and endoplasmic reticulum stress inducer. Tunicamycin (SKU B7417) is widely used in both in vitro and in vivo settings to trigger ER stress and modulate inflammation, as described in the reference study and supporting articles. For detailed protocols and troubleshooting, refer to established workflow guides and product documentation. As always, tunicamycin is intended for research use only and should be handled according to relevant safety and ethical standards.